Lantern Pharma has unveiled a new AI-driven module designed to evaluate the effectiveness of combination cancer therapies involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). The module is part of RADR, Lantern’s proprietary drug discovery platform that combines data analytics, experimental biology, and machine learning to interpret complex biological signals and guide precision oncology research.
